Cost of cancer care varies widely based on who pays the bill
the ONA take:
Cost disparities in chemotherapy drugs can be substantial, reveals a new study from the University of North Carolina and Chapel Hill.
Researchers found uninsured patients with cancer are asked to pay on average 2 times more than Medicare recipients would pay for the same drugs, and that difference can go as high as 43 times more. The uninsured even pay more than those with private insurance.
Cost of doctor visits for cancer patients was also reviewed, and the same discrepancy in costs was seen. For example, uninsured patients were billed $129 to $391, depending on the complexity of the visit; however, Medicare and private insurance paid $65 to $188 and $78 to $246, respectively, for the same visits.
Researchers report that patients with Medicare or private insurance are paying a discounted rate for their health care. Uninsured patients do not have the bargaining power, or may not try to negotiate price on their own.
Uninsured patients with cancer are asked to pay on average 2 times more than Medicare recipients would pay for the same drugs
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Prolactin Expression May Indicate Better Prognosis for Patients With TNBC
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|